📊 SIGY Key Takeaways
Is Sigyn Therapeutics, Inc. (SIGY) a Good Investment?
Sigyn Therapeutics is technically insolvent with negative stockholders' equity of -5.9M and faces an acute liquidity crisis (0.02x current ratio). Operating cash burn of -646.2K combined with minimal cash reserves of 85.6K and 3.5M debt burden indicates the company lacks sufficient financial resources to sustain operations beyond the near term. Despite 405% YoY revenue growth, absolute revenues (4.6K) are negligible and cannot offset -1.4M operating losses.
Why Buy Sigyn Therapeutics, Inc. Stock? SIGY Key Strengths
- Positive gross margin of 55.1% suggests viable unit economics if revenue scales significantly
- Revenue growth of 405.6% YoY demonstrates some market traction and demand
- Company maintains minimal cash position of 85.6K
SIGY Stock Risks: Sigyn Therapeutics, Inc. Investment Risks
- Negative stockholders' equity of -5.9M indicates technical insolvency and balance sheet failure
- Critical liquidity crisis: 0.02x current ratio means only 2% of current liabilities covered by current assets
- Operating cash burn of -646.2K monthly against 85.6K cash reserves implies runway of approximately 1 week
- Long-term debt of 3.5M with total assets of only 135.6K creates unsustainable leverage
- Revenue base of 4.6K per period cannot support -1.4M operating expenses or debt service
- No insider Form 4 filings in past 90 days indicates lack of management confidence
Key Metrics to Watch
- Cash runway (days/weeks remaining at current burn rate)
- Debt restructuring, refinancing, or default status
- Absolute revenue levels and customer concentration
- Operating expense trajectory and path to profitability timeline
Sigyn Therapeutics, Inc. (SIGY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
SIGY Profit Margin, ROE & Profitability Analysis
SIGY vs Healthcare Sector: How Sigyn Therapeutics, Inc. Compares
How Sigyn Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sigyn Therapeutics, Inc. Stock Overvalued? SIGY Valuation Analysis 2026
Based on fundamental analysis, Sigyn Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sigyn Therapeutics, Inc. Balance Sheet: SIGY Debt, Cash & Liquidity
SIGY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sigyn Therapeutics, Inc.'s revenue has grown significantly by 232% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.77 indicates the company is currently unprofitable.
SIGY Revenue Growth, EPS Growth & YoY Performance
SIGY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | $3.8K | -$138.6K | N/A |
| Q2 2020 | $756 | -$62.9K | N/A |
| Q1 2020 | $756 | $54.0K | N/A |
| Q3 2019 | $28.3K | -$138.6K | N/A |
| Q2 2019 | $5.8K | -$62.9K | N/A |
| Q1 2019 | $23.1K | $54.0K | N/A |
| Q3 2018 | $90.5K | -$356.0K | N/A |
| Q2 2018 | $176.9K | -$307.3K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sigyn Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
SIGY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sigyn Therapeutics, Inc. (CIK: 0001642159)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SIGY
What is the AI rating for SIGY?
Sigyn Therapeutics, Inc. (SIGY) has an AI rating of STRONG SELL with 98% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SIGY's key strengths?
Claude: Positive gross margin of 55.1% suggests viable unit economics if revenue scales significantly. Revenue growth of 405.6% YoY demonstrates some market traction and demand.
What are the risks of investing in SIGY?
Claude: Negative stockholders' equity of -5.9M indicates technical insolvency and balance sheet failure. Critical liquidity crisis: 0.02x current ratio means only 2% of current liabilities covered by current assets.
What is SIGY's revenue and growth?
Sigyn Therapeutics, Inc. reported revenue of $4.6K.
Does SIGY pay dividends?
Sigyn Therapeutics, Inc. does not currently pay dividends.
Where can I find SIGY SEC filings?
Official SEC filings for Sigyn Therapeutics, Inc. (CIK: 0001642159) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SIGY's EPS?
Sigyn Therapeutics, Inc. has a diluted EPS of $-1.68.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SIGY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Sigyn Therapeutics, Inc. has a STRONG SELL rating with 98% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SIGY stock overvalued or undervalued?
Valuation metrics for SIGY: ROE of N/A (sector avg: 15%), net margin of -58,785.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SIGY stock in 2026?
Our dual AI analysis gives Sigyn Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SIGY's free cash flow?
Sigyn Therapeutics, Inc.'s operating cash flow is $-646.2K, with capital expenditures of $860.0. FCF margin is -14,097.3%.
How does SIGY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -58,785.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.02 (avg: 2).